Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Open accessThe DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
Abstract
The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other’s work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general, European and US guidelines recommend more-restrictive criteria for resection than Asian guidelines7,22–27.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [23]
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,700
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Cited by
Items 601–678 of 678
Gao, Y.-M., Tang, S., Luo, Z.-W., Zhi, W., Yan, X., Yin, X. H., Bi, X., & Yue, H. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i11.112212
Su, D., Zhang, X., Wu, Y., Sun, K., Chen, Y., & Xiao, W. (2025) · BMC Cancer · doi:10.1186/s12885-025-15365-5
Liu, J., Zhao, Z., Tian, Y., & Shao, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-04132-4
“The HCC practice guidelines of the Japanese Society of Hepatology have recognized HAIC as an effective treatment for locally advanced HCC, particularly suitable for patients with greater tumor burden with vascular invasion [11].”
Li, L., Li, Z., Zhang, Y., Zhu, S., Ni, Y., Xu, L., Yan, S., & Tang, Y. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s571169
“19,20 Furthermore, a recent study from Japan classified portal vein invasion (Vp) classification 2–3 type PVTT as “borderline resectable 1”, suggesting that LR, as the core of the multidisciplinary treatment strategy, may provide survival benefits.”
Tajima, K., Miuma, S., Sasaki, R., Kanda, Y., Matsuo, S., Shimakura, A., Takahashi, K., Nakao, Y., Fukushima, M., Haraguchi, M., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70102 · Cited by 1
Lin, W., Wang, K., Pan, C., & Ma, L. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04164-8
“…as endorsed by the Japanese Society of Hepatology (JSH) consensus statements and the Chinese National Liver Cancer (CNLC) consensus guidelines in appropriately selected cases [11, 12], although it is not recommended by BCLC staging, in which systemic therapy is recommended as the sole treatment.”
Kim, J. H., Kim, H. S., Yoon, J. H., Joo, I., Yoon, J.-H., Kim, Y. J., Yu, S. J., & Lee, J. M. (2023) · Figshare · doi:10.6084/m9.figshare.24002712
Tian, C., Wang, Z., Huang, L., Liu, Y., Wu, K., Li, Z., Han, B., 焦德超, Han, X., & Zhao, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21314283
Matsufuji, S., Kitajima, Y., Higure, K., Kimura, N., Maeda, S., Yamada, K., Ito, K., Tanaka, T., Kai, K., & Noshiro, H. (2023) · Figshare · doi:10.6084/m9.figshare.24779208
Matsufuji, S., Kitajima, Y., Higure, K., Kimura, N., Maeda, S., Yamada, K., Ito, K., Tanaka, T., Kai, K., & Noshiro, H. (2023) · Figshare · doi:10.6084/m9.figshare.26651469
Ye, J., Lu, H.-Z., Zeng, C., Lei, G., Wang, X.-B., Chen, J., Bai, T., Wu, F., Mai, R.-Y., Guo, W.-X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26103765
Liu, C., Wu, S., Lai, L., Liu, J., Guo, Z., Ye, Z., & Chen, X. (2023) · Figshare · doi:10.6084/m9.figshare.22599751
Guo, Y., Wu, J., Liang, L., Zhu, K., Zhou, J., Lin, L., Chen, Y., Cao, B., 何明基, Lian, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24196757
Guo, Y., Wu, J., Liang, L., Zhu, K., Zhou, J., Lin, L., Chen, Y., Cao, B., 何明基, Lian, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24196760
Matsufuji, S., Kitajima, Y., Higure, K., Kimura, N., Maeda, S., Yamada, K., Ito, K., Tanaka, T., Kai, K., & Noshiro, H. (2023) · Figshare · doi:10.6084/m9.figshare.24779399
Ye, J., Lu, H., Zeng, C., Lei, G., Wang, X.-B., Chen, J., Bai, T., Wu, F., Mai, R.-Y., Guo, W.-X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26103980
Matsufuji, S., Kitajima, Y., Higure, K., Kimura, N., Maeda, S., Yamada, K., Ito, K., Tanaka, T., Kai, K., & Noshiro, H. (2023) · Figshare · doi:10.6084/m9.figshare.26651472
Matsufuji, S., Kitajima, Y., Higure, K., Kimura, N., Maeda, S., Yamada, K., Ito, K., Tanaka, T., Kai, K., & Noshiro, H. (2023) · Figshare · doi:10.6084/m9.figshare.26651466
Ding, W., Tian, X., Yang, Y., Xu, H., Li, X., Yu, J., & Liang, P. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251403407
“8 For concentrated distributed tumors, laparoscopic hepatectomy (LH) can simultaneously remove multiple tumors at one time without causing excessive damage to the liver parenchyma.”
Lin, W.-M., Huang, H., Lu, S., Yang, T.-Y., Wang, H., Hsu, S.-L., Lai, C., & Chang, T. (2025) · Diagnostics · doi:10.3390/diagnostics16010115
Nakabori, T., Kawabata, M., Mukai, K., Hongyo, H., Maeda, N., Urabe, M., Kai, Y., Takada, R., Ikezawa, K., Wada, H., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.71552
“Consequently, these regimens have received global approval as first-line systemic therapies for unresectable HCC [4–6].”
Hayasaki, A., Nagata, M., Usui, M., Imai, H., Iizawa, Y., Tanemura, A., Murata, Y., Kuriyama, N., Kishiwada, M., & MIZUNO, S. (2026) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.70186
“In HCC with PVTT, although a global treatment standard is lacking, a variety of strategies have been reported, such as molecular targeted therapy, transcatheter arterial chemoembolization, hepatectomy, and hepatic arterial infusion chemotherapy [19, 27, 28].”
FUJITA, K., Takuma, K., Nakahara, M., Suto, H., Morishita, A., Himoto, T., Okano, K., & Kobara, H. (2026) · Cancer Medicine · doi:10.1002/cam4.71594
“In terms of post-TACE therapeutic strategies, an emerging trend in systemic therapy is being carefully applied in patients with CVTs. Recently, angiogenesis inhibitors have been adopted as the first or second choice of treatment for unresectable HCC in therapeutic guidelines [37–39].”
Rinka, K., Kioka, K., Shioji, R., Adachi, M., Kashima, T., Ikeda, T., Yamaguchi, T., Fukui, N., Sakata, Y., Ochiai, T., et al. (2026) · Internal Medicine · doi:10.2169/internalmedicine.6699-25
Chen, X., Yang, D., Lin, L., Wu, A., Huang, L., Mao, L., Xia, H.-S., & Lu, Q. (2026) · ULTRASONOGRAPHY · doi:10.14366/usg.25148 · Cited by 1
“Accordingly, recent guidelines from the Japan Society of Hepatology (JSH) and the Korean Liver Cancer Association–National Cancer Center (KLCA-NCC) have incorporated KP hypoenhancement as a major diagnostic criterion for HCC [8,9].”
Ultrasound-guided ablation of hepatocellular carcinoma: a review of its past, present, and future
Gu, K., Rhim, H., Lee, M. W., & Han, S. (2026) · ULTRASONOGRAPHY · doi:10.14366/usg.25264
“…Cancer Center, ACTA, and the Japanese Society of Hepatology—recommend RFA as a primary treatment option for small HCCs ( 3 cm), advocate combined transarterial chemoembolization (TACE) and ablation for tumors measuring 3–5 cm, and recognize MWA and cryoablation as comparable alternatives [2,3,32].”
Zhu, L., Patil, S. A., Kuhlers, P. C., Moon, A. M., Raab, J. R., Pfefferle, A. D., Hayward, M. C., Wielgus, A. R., la Cruz, G. D., Bantumilli, S., et al. (2026) · Pathology · doi:10.1016/j.pathol.2025.12.006
Li, J., Yang, Y., Deng, R., Zhou, J., Xv, X., Chong, H., Liu, P., Wu, P., Weng, J., Chen, Y., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8993132/v1
Value of des-gamma-carboxy prothrombin in comprehensive management of hepatocellular carcinoma
Liu, Z.-H., Wang, W.-J., & Dang, S. (2026) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v34.i2.110
Hwang, Y., Heo, S., An, J., Na, S. K., Kim, S., Song, I. H., Nault, J., Song, G.-W., Choi, S. H., & Shim, J. H. (2026) · Liver Cancer · doi:10.1159/000551666
Zhu, X., & Sun, H. (2026) · Clinical Surgical Oncology · doi:10.1016/j.cson.2026.100127
Hepatocellular Carcinoma in the Eastern World: Screening, Diagnosis, Staging and Treatment
Wu, T., Cheng, C., Wang, Y.-C., Hung, H., Lee, J., Lai, Y. H., Wu, T.-J., Chou, H., Lee, C.-F., Lee, W., et al. (2026) · Current Pharmaceutical Design · doi:10.2174/0113816128435921260221114109
Tanaka, K., Tsuji, K., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70178
“Atez/ Bev has been approved as a first‐line therapy for unresectable advanced HCC in several Western and Eastern countries [2–5].”
Self-citationYang, J., Shi, F., Jiang, N., Zhang, S., Yin, Y., Yu, B., Feng, W., Chu, H., & Ni, C. (2026) · Clinical Medicine Insights Oncology · doi:10.1177/11795549261441338
“19,20 Repeated TACE procedures in these patients may reduce treatment sen sitivity, ultimately leading to TACE refractoriness.”
Aoe, K., Tada, T., Hiraoka, A., Matono, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001781 · Cited by 1
Self-citationXiao, Y., Song, W., Liu, H., Yang, Q., Zhou, J., & Guo, D. (2026) · BMC Medical Imaging · doi:10.1186/s12880-026-02371-7 · Cited by 1
“The study adopted 2021 revised expert consensus criteria established by Japan Society of Hepatology (JSH) [4], with whether TACE refractoriness occurs as evaluation end-point.”
Maruta, S., Koshima, Y., Debari, Y., Sugihara, C., 高畑豪, Tamura, R., Ohshima, T., Ono, Y., Morita, Y., Chiba, T., et al. (2026) · Current Oncology · doi:10.3390/curroncol33050286
“In this context, locoregional therapies (LRT) play a central role in the management of HCC in Asian countries [13–15].”
Murakami, T., Hatanaka, T., Tateyama, Y., Tojima, H., Yamazaki, Y., Miyasaka, Y., Shibuya, K., Naganuma, A., Kakizaki, S., Ohno, T., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70206
Self-citationKim, J.-Y., Kim, D. W., Kim, D. W., Ko, E., Kim, J., Gwon, D. I., & Shin, J. H. (2026) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2026.108861
Wu, D., Song, Z., Tang, J., Miao, H., Tian, M., Fan, W., Du, J., Lu, Z., Zhang, H., & Zhang, Y. (2026) · Cancers · doi:10.3390/cancers18111776
“Therefore, combination therapy incorporating intensive locoregional approaches such as TACE and HAIC is favoured as an initial treatment strategy [14,15].”
Ma, X., Wang, J., & Li, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1822689
“(11, 12).”
Li, F., Zhang, J., An, X., Liu, J., Li, B., Li, H., Li, J. N., Wang, N., Jiang, G., Jiang, Y., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1761615
Nakabori, T., Mukai, K., Miyanaga, T., Takiyama, H., Sekiya, K., Kinomoto, T., Masumoto, T., Murata, J., Urabe, M., Kai, Y., et al. (2026) · Cancers · doi:10.3390/cancers18111800
“…landscape of advanced-stage HCC has evolved substantially with the introduction of combination immunotherapies, including atezolizumab plus bevacizumab (atezo/bev), tremelimumab plus durvalumab, and nivolumab plus ipilimumab, which are the current standard first-line systemic treatments [9–14].”
Krishnan, A. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.120606
Outcomes of radiotherapy of hepatocellular carcinoma: a retrospective analysis
Rudat, V., Li, J., Zhao, R., Shi, Y., Huang, L., Qiu, M., Li, J., Zhu, A. X., & 严以群 (2026) · Radiation Oncology · doi:10.1186/s13014-026-02869-y
“Owing to the still low number of prospective studies, others have not yet done so [15, 16].”
Lai, Z., Ge, A., Ouyang, H., Wu, Z., Huang, Y., Li, Q., Xu, L., Li, B., Chen, M. S., Wen, D., et al. (2026) · MedComm · doi:10.1002/mco2.70805
Brancaccio, G., Vitale, A., Russo, F. P., Cabibbo, G., Gruttadauria, S., Pagano, D., Sandri, G. B. L., Giannelli, V., Cescon, M., Sposito, C., et al. (2026) · Liver International · doi:10.1111/liv.70738
“This approach is consistent with Asia Pacific guidelines [17] and the Japan Society of Hepatology, which recommends both resection and radiofrequency ablation [18].”
Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinoma
Tanaka, K., Tsuji, K., Hiraoka, A., Tada, T., Kariyama, K., Itobayashi, E., Ishikawa, T., Toyoda, H., Koshiyama, Y., Hatanaka, T., et al. (2026) · Hepatology International · doi:10.1007/s12072-026-11110-7
Self-citationvon Schoen-Angerer, G., Pesola, G., Garo, M. L., Marini, G., Cappio, S., Andreas, C., Magenta, L., Majno-Hurst, P., Bernardi, L., Cefalì, M., et al. (2026) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s598858
LI-RADS v2018 versus KLCA-NCC v2022: comparison of probability-based HCC categories
Yoon, J. H., Lee, E. S., Kim, Y. W., Lee, C. H., Kim, J. W., Chang, W., Choi, J., Park, B. J., Choi, J.-Y., Kim, S., et al. (2026) · European Radiology · doi:10.1007/s00330-026-12696-0
Cao, M., Lin, M., Deng, Y., & Jiang, J. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1831463
Xu, Y., Zhang, C., Ji, Z., Liu, C., Cai, L., Wang, C., Liao, H., Wen, Y., Chi, L., Li, C., et al. (2026) · Research · doi:10.34133/research.1372 · Cited by 1
“Initially, patients were clinically diagnosed with IM-mHCC based on integrated imaging and pathological criteria [ 17 ]: (a) Each patient had at least 2 independent tumors that were mostly distributed in the same liver lobe or adjacent segments.”
Huang, J., Lin, K., Zhong, X., Long, H., Xie, X. C., Zhuang, B., & Lin, M. (2026) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2026.06.007
Yamamoto, Y., Asahi, Y., Shichi, S., Fujii, Y., Sakamoto, Y., Fujiyoshi, S., Imaizumi, K., Aiyama, T., Nagatsu, A., Orimo, T., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70240
Chen, Y., Li, W.-F., Chen, Y.-H., Tsai, M., Kuo, Y., Wang, J.-H., Chen, C.-H., Lu, S., Wang, C.-C., & Hung, C. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04476-y
Yuza, K., & Pawlik, T. M. (2026) · Cancers · doi:10.3390/cancers18142234
Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Nishimura, T., Tsuji, K., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70239
Self-citationIkuta, S., Aihara, T., Nakajima, T., Iwasaki, T., & Yamanaka, N. (2026) · Updates in Surgery · doi:10.1007/s13304-026-02773-w
Shi, Z., Han, L., He, T., & Shen, M. (2026) · Medicine · doi:10.1097/md.0000000000049992
“[7,8] Both transarterial chemoembolization (TACE) and HAIC have demonstrated efficacy in advanced or unresectable HCC. [9] Unlike TACE, HAIC emphasizes continuous arterial drug administration.”
Takehara, Y., Saito, Y., Morine, Y., Yamada, S., Teraoku, H., Waki, Y., Ikemoto, T., & Shimada, M. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03141-9
Self-citationChen, B., Zeng, Y., Abdugheni, K., Zeng, L., Dai, H., Tang, K., Zhang, G., Yang, J., Huang, Y., & Lin, R. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00291
Zhao, L., Liu, D., Ma, C., Hu, Y., & Liu, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1880527
“Both Chinese and Japanese guidelines recommend HAIC, particularly for advanced HCC with major PVTT (9, 10).”
MRI of Hepatocellular Carcinoma: Cross-regional Perspectives on Trends and Opportunities
Tan, C. H., Jiang, H., Wang, Y., Low, H. M., Welle, C. L., Zhou, S., Brancatelli, G., Venkatesh, S. K., & Lee, J. M. (2026) · Radiographics · doi:10.1148/rg.260001 · Cited by 1
Jin, S., Wang, Q., Zhu, L., Teng, D., Sui, G., & Wang, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1854471
“Current Japanese and international guidance emphasizes individualized HCC management and the appropriate selection of imaging and locoregional treatment strategies (19, 20).”
Haowen, T., Yuhao, H., Cao, Y., Xiangfei, M., Zhanyu, Y., & ShiChun, L. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01554-3
Wang, J., Sun, Y., Chen, L., Wang, Z., Li, K., Guo, Y., Yao, L., Duan, L., & Liu, Q. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-119746
Shirataki, H., Mizumoto, M., Iizumi, T., Saito, T., Numajiri, H., Harada, M., Sawada, T., Goto, M., Sumiya, T., Fujisawa, T., et al. (2026) · Cancers · doi:10.3390/cancers18183005
“…feasible for a substantial proportion of patients because of impaired liver function, unfavorable tumor size or location, vascular invasion, comorbidities, or other factors that limit surgical or invasive local treatment, underscoring the need for effective alternative locoregional therapies [2–4].”
Yen, Y., Yong, C., Liu, Y., Li, W.-F., Wang, C., & Lin, C. (2026) · Cancer Reports · doi:10.1002/cnr2.70697
“Kudo et al. suggested that patients with BCLC B HCC and beyond up- to-seven criteria should undergo systemic therapies [29].”
Adachi, Y., Shimada, S., Mizukami, S., Takizawa, T., Enomoto, K., Makino, K., Takahashi, H., Takahashi, H., Imai, K., & Yokoo, H. (2026) · Nutrients · doi:10.3390/nu18193147
Hepatocellular- cholangiocarcinoma collision tumor: a case report
Cao, H., Lin, L., Xie, C., Liu, Y., Zou, J., & Sun, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1860896
Zhou, S., Yang, J., Zhang, S., Song, Y., Li, S., Yu, X., Wang, S., Ju, S., You, T., & Wang, Y. (2026) · Insights into Imaging · doi:10.1186/s13244-026-02402-5
“…Cancer Center (KLCA – NCC, v2022, largely consistent with v2018 in de fi nite HCC criteria) [4], the Japan Society of Hepatology (JSH, v2021) [5], and the Asian Paci fi c Association for the Study of the Liver (APASL, v2017) [6], incorporate HBP hypointensity as a major diagnostic feature,…”
Jung, J., Lee, H. A., Kim, D. Y., Kang, H.-C., Bae, S. H., Min, J. H., Yoo, G. S., Yu, J. I., Choi, S. H., Lee, H. L., et al. (2026) · Radiation Oncology Journal · doi:10.3857/roj.2026.01011
Rosa‐Sánchez, C., López-Garrido, M. A., Valverde‐López, F., & Redondo‐Cerezo, E. (2026) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.70182
He, Y.-X., Dai, H.-C., Pan, S.-T., Zhang, Y.-Z., Tang, Y.-Z., Liu, Y., & Zhou, H.-F. (2026) · Academic Radiology · doi:10.1016/j.acra.2026.09.028
Yuan, M., Wang, D., Shi, Z., Sun, Z., Zhao, Y., Yan, T., Yuan, Y., Xu, Z., & Jiang, H. (2026) · Abdominal Radiology · doi:10.1007/s00261-026-05810-9
Zhang, X., Shi, S., Su, Y., Ma, Y., Guo, Q., Xuerou, M., Wang, R., Long, J., Yang, J., & Xiong, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1917667
“Furthermore, the Japan Society of Hepatology (JSH) guidelines explicitly recommend HAIC as one of the fi rst-line treatment options for patients with portal vein involvement (14).”
Himoto, T., Fujita, K., & Morishita, A. (2026) · Livers · doi:10.3390/livers6050102
Wang, Z., Yin, N., Su, R., Zhou, M., Sun, Z., Jiaying, L., & 陈立天 (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1772206
“While TACE has gained widespread clinical adoption, particularly in Asian populations (3, 4), substantial heterogeneity in treatment response remains a signi fi cant challenge, with a subset of patients demonstrating limited therapeutic bene fi t (5).”
Metadata
- Authors
- Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., Izumi, N., Moriguchi, M., Ogasawara, S., Minami, Y., Ueshima, K., Murakami, T., Miyayama, S., Nakashima, O., Yano, H., Sakamoto, M., Hatano, E., Shimada, M., Kokudo, N., Mochida, S., Takehara, T., & HCC Expert Panel of the Japan Society of Hepatology
- Affiliations
- Kindai University Hospital (JP)
- Toranomon Hospital (JP)
- The University of Tokyo (JP)
- Okayama City Hospital (JP)
- Juntendo University (JP)
- Ogaki Municipal Hospital (JP)
- Ikeda Municipal Hospital (JP)
- Ehime Prefectural Central Hospital (JP)
- National Cancer Center Hospital East (JP)
- Musashino Red Cross Hospital (JP)
- Kyoto Prefectural University of Medicine (JP)
- Chiba University (JP)
- Kobe University (JP)
- Fukui-ken Saiseikai Hospital (JP)
- Kurume University (JP)
- Keio University (JP)
- Hyogo Medical University (JP)
- Tokushima University (JP)
- National Center for Global Health and Medicine (JP)
- Saitama Medical University (JP)
- The University of Osaka (JP)
- ORCID
- Kudo, Masatoshi
- Kawamura, Yusuke
- Hasegawa, Kiyoshi
- Tateishi, Ryosuke
- Kariyama, Kazuya
- Shiina, Shuichiro
- Toyoda, Hidenori
- Hiraoka, Atsushi
- Ikeda, Masafumi
- Izumi, Namiki
- Moriguchi, Michihisa
- Ogasawara, Sadahisa
- Minami, Yasunori
- Ueshima, Kazuomi
- Murakami, Takamichi
- Miyayama, Shiro
- Nakashima, Osamu
- Yano, Hirohisa
- Sakamoto, Michiie
- Hatano, Etsuro
- Shimada, Mitsuo
- Kokudo, Norihiro
- Mochida, Satoshi
- Takehara, Tetsuo
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2021
- Volume
- 10
- Issue
- 3
- Pages
- 181-223
- ISSN
- 1664-5553 (ISSN-L)
- 2235-1795
- PMC
- PMC8237791
- OpenAlex
- W3162270595
- Cited by
- 678
- References
- 200
- Citations by year
- 2026: 78 · 2025: 137 · 2024: 158 · 2023: 177 · 2022: 108 · 2021: 17
- FWCI
- 14.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Liver Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc)
- Funders
- Japan Society for the Promotion of Science (19K08199)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, consensus statement, clinical guidelines, HCC diagnosis, HCC treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.